Tivic

Tivic Health is a biotechnology company transitioning into a strategic biopharma player with a late-stage, host-protection immunotherapy platform. Its core technology, the TLR5 agonist Entolimod, is being developed as a military countermeasure for Acute Radiation Syndrome and has potential applications in oncology supportive care (e.g., Neutropenia) and chronic diseases. The company vertically integrates its R&D with a wholly-owned CDMO subsidiary, Velocity Bioworks, providing manufacturing control and a secondary revenue stream while de-risking its pipeline development.

TLR5 agonist platform for host-protection and cytoprotection, activating innate immunity to prevent cell death and promote tissue regeneration in bone marrow and epithelial tissues.

In ARS, Tivic competes with other biodefense companies developing radiation countermeasures (e.g., Neumora, others in BARDA portfolio). In Neutropenia, the competitive landscape is dominated by branded and biosimilar granulocyte colony-stimulating factors (G-CSFs) like Neulasta, requiring Entolimod to demonstrate a differentiated clinical profile.